CLS signs supplier agreement with University of Texas Medical Branch and receives the first order
Clinical Laserthermia Systems (CLS) (publ), has through its subsidiary CLS Americas Inc. signed a supplier agreement with University of Texas Medical Branch (UTMB). The agreement means that CLS is an approved supplier to UTMB, which is a prerequisite for the company when delivering equipment to the hospital. An agreement of this kind does not contain any obligations when it comes to future orders or volumes, however UTMB has placed the first order for CLS’ single use accessories for MR-guided laser ablation. The order value amounts to about 40 000 SEK.
Earlier this year the company announced that UTMB had used CLS’ single use accessories when treating three patients with early stage tumors in the prostate. The purpose was to evaluate the products for MR-guided laser ablation and resulted in, inter alia, that CLS is now an approved supplier to UTMB.
- We have further developed the collaboration with UTMB and moved forward in the process that was initiated in May this year. The relationship with UTMB and Dr. Eric Walser is important to us also in other ongoing discussions in the US. We believe that we are seeing the beginning of a commercial acceptance for our products’ features and pricing, and that we thereby are able to compete with bigger and more established suppliers within our market segment, said Dan Mogren, Chief Commercial Officer at CLS.
CLS and UTMB signed a Letter of Intent in August 2016, aiming to establish the use of the TRANBERG® products for MR-guided laser ablation as part of standard treatment for cancer patients.
Read more about University of Texas Medical Branch: www.utmb.edu
This information is such that Clinical Laserthermia Systems AB (publ) is required to publish pursuant to the EE Market Abuse Directive. The contact person arranged for the release of this information on 19 October 2017, at 04:00 PM.
Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00 E-mail: email@example.com
Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG®|Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immunostimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and has a subsidiary in Berlin, Germany and Boston, MA,USA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on the company’s website: www.clinicallaser.se